Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Updates on the coronavirus disease 2019 vaccine and consideration in children

  • Kang, Hyun Mi (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Choi, Eun Hwa (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Yae-Jean (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2021.05.21
  • Accepted : 2021.06.03
  • Published : 2021.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Humanity has been suffering from the global severe acute respiratory syndrome coronavirus 2 pandemic that began late in 2019. In 2020, for the first time in history, new vaccine platforms-including mRNA vaccines and viral vector-based DNA vaccines-have been given emergency use authorization, leading to mass vaccinations. The purpose of this article is to review the currently most widely used coronavirus disease 2019 vaccines, investigate their immunogenicity and efficacy data, and analyze the vaccine safety profiles that have been published, to date.

Keywords

Acknowledgement

We would like to express our gratitude to Kyung-Ran Kim, Doo Ri Kim, Ye-Ji Kim, and Hwanhee Park for reviewing the data of the studies described in this manuscript.

References

  1. Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci U S A 2004;101:6146-51. https://doi.org/10.1073/pnas.0307506101
  2. Peak CM, Childs LM, Grad YH, Buckee CO. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci U S A 2017;114:4023-8. https://doi.org/10.1073/pnas.1616438114
  3. Weber DJ, Rutala WA, Fischer WA, Kanamori H, Sickbert-Bennett EE. Emerging infectious diseases: focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9). Am J Infect Control 2016;44(5 Suppl):e91-100.
  4. Park Y, Huh IS, Lee J, Kang CR, Cho SI, Ham HJ, et al. Application of testing-tracing-treatment strategy in response to the COVID-19 outbreak in Seoul, Korea. J Korean Med Sci 2020;35:e396. https://doi.org/10.3346/jkms.2020.35.e396
  5. Haber MJ, Shay DK, Davis XM, Patel R, Jin X, Weintraub E, et al. Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic. Emerg Infect Dis 2007;13:581-9. https://doi.org/10.3201/eid1304.060828
  6. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. Geneva (Switzerland): World Health Organization; 2021 [cited 2021 Mar 12]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
  7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74. https://doi.org/10.1016/s0140-6736(20)30251-8
  8. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;1866:165878. https://doi.org/10.1016/j.bbadis.2020.165878
  9. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92.e6. https://doi.org/10.1016/j.cell.2020.02.058
  10. Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci 2020;257:118056. https://doi.org/10.1016/j.lfs.2020.118056
  11. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020;41:1141-9. https://doi.org/10.1038/s41401-020-0485-4
  12. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9:382-5. https://doi.org/10.1080/22221751.2020.1729069
  13. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439-50. https://doi.org/10.1056/NEJMoa2027906
  14. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020;383:1920-31. https://doi.org/10.1056/NEJMoa2022483
  15. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020;396:467-78. https://doi.org/10.1016/S0140-6736(20)31604-4
  16. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a Trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021;384:1824-35. https://doi.org/10.1056/NEJMoa2034201
  17. World Health Organization. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process [Internet]. Geneva (Switzerland): World Health Organization; 2021 [cited 2021 Mar 12]. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_10March2021.pdf.
  18. Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology 2018;153:1-9. https://doi.org/10.1111/imm.12829
  19. Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021;21:73-82. https://doi.org/10.1038/s41577-020-00480-0
  20. Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-27. https://doi.org/10.1038/s41586-020-2798-3
  21. Pichichero ME. Understanding messenger RNA and other SARS-CoV-2 vaccines [Internet]. Parsippany (NJ): Frontline Medical Communications Inc.; 2020 [cited 2021 Mar 12]. Available from: https://www.mdedge.com/hematology-oncology/article/233491/coronavirus-updates/understanding-messenger-rna-and-other-sars.
  22. Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020;586:567-71. https://doi.org/10.1038/s41586-020-2622-0
  23. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 2020;383:1544-55. https://doi.org/10.1056/NEJMoa2024671
  24. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther 2014;22:668-74. https://doi.org/10.1038/mt.2013.284
  25. Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum Vaccin Immunother 2016;12:2064-74. https://doi.org/10.1080/21645515.2016.1165908
  26. Afrough S, Rhodes S, Evans T, White R, Benest J. Immunologic dose-response to adenovirus-vectored vaccines in animals and humans: a systematic review of dose-response studies of replication incompetent adenoviral vaccine vectors when given via an intramuscular or subcutaneous route. Vaccines (Basel) 2020;8:131. https://doi.org/10.3390/vaccines8010131
  27. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15. https://doi.org/10.1056/NEJMoa2034577
  28. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16. https://doi.org/10.1056/NEJMoa2035389
  29. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
  30. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021;397:881-91. https://doi.org/10.1016/S0140-6736(21)00432-3
  31. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384:2187-201. https://doi.org/10.1056/NEJMoa2101544
  32. U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee. COVID-19 vaccine Ad26.COV2.S. Sponsor Briefing Document [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2021 [cited 2021 Feb 21]. Available from: https://www.fda.gov/media/146219/download.
  33. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 2021;384:1964-5. https://doi.org/10.1056/NEJMc2105869
  34. Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124-30. https://doi.org/10.1056/NEJMoa2104882
  35. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092-101. https://doi.org/10.1056/NEJMoa2104840
  36. European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets [Internet]. Amsterdam (Netherlands): European Medicines Agency; 2021 [cited 2021 Mar 20]. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possiblelink-very-rare-cases-unusual-blood-clots-low-blood.
  37. European Medicines Agency. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine's benefits currently still outweigh risks - Update [Internet]. Amsterdam (Netherlands): European Medicines Agency; 2021 [cited 2021 Apr 1]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-pracinvestigating-cases-thromboembolic-events-vaccines-benefits.
  38. Ostergaard SD, Schmidt M, Horvath-Puho E, Thomsen RW, Sorensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 2021;397:1441-3. https://doi.org/10.1016/S0140-6736(21)00762-5
  39. Mahase E. AstraZeneca vaccine: blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. BMJ 2021;373:n931. https://doi.org/10.1136/bmj.n931
  40. Korea Disease Control and Prevention Agency. Recommencement of the AstraZeneca vaccine that was placed on hold, starting April 12 [Internet]. Cheongju (Korea): Korea Disease Control and Prevention Agency; 2021 [cited 2021 Apr 27]. Available from: http://www.kdca.go.kr/gallery.es?mid=a20503030300&bid=0004&b_list=9&act=view&list_no=145062&nPage=1&vlist_no_npage=1&keyField=&keyWord=&orderby=.
  41. Centers for Disease Control and Prevention. J&J/Janssen update [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2021 Apr 27]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html.
  42. U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2021 [cited 2021 Feb 21]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizerbiontech-covid-19-vaccine-emergency-use.
  43. Pfizer. Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in adolescents [Internet]. New York: Pfizer; 2021 [cited 2021 Mar 31]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positivetopline-results-pivotal.
  44. Moderna. Kidcove Study Trial ID: NCT04796896 [Internet]. Cambridge (MA): Moderna; 2021 [cited 2021 Mar 31]. Available from: https://connect.trialscope.com/studies/0e8fc8e6-5782-46fd-8b03-0994a5ad8b41.
  45. ModernaTX Inc. A study to evaluate safety and effectiveness of mRNA-1273 vaccine in healthy children between 6 months of age and less than 12 years of age [Internet]. Cambridge (MA): Moderna; 2021 [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04796896.
  46. National Institute for Health Research. First children's COVID-19 vaccine trial open [Internet]. London: National Institute for Health Research; 2021 [cited 2021 Mar 31]. Available from: https://www.nihr.ac.uk/news/first-childrens-covid-19-vaccine-trial-open/26870.
  47. Johnson & Johnson. Johnson & Johnson expands phase 2a clinical trial of COVID-19 vaccine candidate to include adolescents [Internet]. New Brunswick (NJ): Johnson & Johnson; 2021 [cited 2021 Apr 27]. Available from: https://www.jnj.com/johnson-johnson-expands-phase2a-clinical-trial-of-covid-19-vaccine-candidate-to-include-adolescents.
  48. United Nations. Population Division (2019). World Population Prospects 2019, custom data acquired via website [Internet]. New York: United Nations; 2021 [cited 2021 Apr 14]. Available from: https://population.un.org/wpp/DataQuery/.
  49. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663-5. https://doi.org/10.1056/NEJMc2005073
  50. Han MS, Choi EH, Chang SH, Jin BL, Lee EJ, Kim BN, et al. Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea. JAMA Pediatr 2021;175:73-80. https://doi.org/10.1001/jamapediatrics.2020.3988
  51. Jiehao C, Jin X, Daojiong L, Zhi Y, Lei X, Zhenghai Q, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 2020;71:1547-51. https://doi.org/10.1093/cid/ciaa198
  52. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of Covid-19 in children in early January 2020 in Wuhan, China. N Engl J Med 2020;382:1370-1. https://doi.org/10.1056/NEJMc2003717
  53. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020;20:689-96. https://doi.org/10.1016/s1473-3099(20)30198-5
  54. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125-32. https://doi.org/10.3345/cep.2020.00535
  55. American Academy of Pediatrics. Children and COVID-19: state-level data report [Internet]. Itasca (IL): American Academy of Pediatrics; 2021 [cited 2021 Apr 2]. Available from: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/.
  56. Centers for Disease Control and Prevention. 2019-20 Season's pediatric flu deaths tie high mark set during 2017-18 season [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2021 Mar 4]. Available from: https://www.cdc.gov/flu/spotlights/2019-2020/2019-20-pediatric-flu-deaths.htm#:~:text=LinkedIn-,2019%2D20%20Season's%20Pediatric%20Flu%20Deaths%20Tie%20High,Set%20During%202017%2D18%20Season&text=August%2021%2C%202020%20%E2%80%93%20CDC%20today,for%20last%20season%20to%20188.
  57. Goodman B. Children likely the 'leading edge' in spread of COVID-19 variants [Internet]. New York: Medscape LLC; 2021 [cited 2021 Mar 31]. Available from: https://www.medscape.com/viewarticle/948584.
  58. Klass P, Ratner AJ. Vaccinating Children against Covid-19 - The Lessons of Measles. N Engl J Med 2021;384:589-91. https://doi.org/10.1056/NEJMp2034765
  59. Anderson EJ, Campbell JD, Creech CB, Frenck R, Kamidani S, Munoz FM, et al. Warp Speed for COVID-19 Vaccines: Why are Children Stuck in Neutral? Clin Infect Dis 2020 Sep 18;ciaa1425. https://doi.org/10.1093/cid/ciaa1425. Epub.
  60. Wong BLH, Ramsay ME, Ladhani SN. Should children be vaccinated against COVID-19 now? Arch Dis Child 2021 Jan 5:archdischild-2020-321225. https://doi.org/10.1136/archdischild-2020-321225. Epub.
  61. AAP News and Journals. Children make up nearly 21% of new COVID-19 cases [Internet]. Itasca (IL): American Academy of Pediatrics; 2021 [cited 2021 May 28]. Available from: https://www.aappublications.org/news/2021/04/19/pediatric-covid-cases-041921.

Cited by

  1. Pediatric and Parents' Attitudes Towards COVID-19 Vaccines and Intention to Vaccinate for Children vol.36, pp.31, 2021, https://doi.org/10.3346/jkms.2021.36.e227
  2. Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study vol.36, pp.32, 2021, https://doi.org/10.3346/jkms.2021.36.e232
  3. Updates on Coronavirus Disease 19 Vaccine and Its Clinical Application vol.11, pp.4, 2021, https://doi.org/10.21215/kjfp.2021.11.4.236